Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 9Prostatic Neoplasms 5Neoplasms 5Neoplasm Metastasis 4Advanced Solid Tumors 4Leukemia, Myeloid, Acute 3Triple Negative Breast Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Carcinoma, Renal Cell 2Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Recurrent Squamous Cell Lung Carcinoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Myelodysplastic Syndromes 1Lymphoma, Mantle-Cell 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Kidney Neoplasms 1Glioma 1Glioblastoma 1Fanconi Anemia, Complementation Group D1 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Childhood Solid Tumors 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Adenocarcinoma 1Advanced Solid Tumor 1

Interventions

Radiotherapy 83Temozolomide 78Filgrastim 34Carboplatin 33Vincristine 29Etoposide 26Cyclophosphamide 25Carmustine 25Irinotecan 23Chemotherapy, Adjuvant 23Cisplatin 21Peripheral Blood Stem Cell Transplantation 20Thiotepa 14Lomustine 14Granulocyte Colony-Stimulating Factor 13Surgical Procedures, Operative 12Procarbazine 12Bevacizumab 11Thalidomide 10O(6)-benzylguanine 10Drug Therapy 10etoposide phosphate 9Methotrexate 9Magnetic Resonance Spectroscopy 9Gene Expression Profiling 9Radiation 8Paclitaxel 8sargramostim 7Ifosfamide 7Everolimus 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Central Nervous System Neoplasms × talazoparib × Clear all
NCT02116777 2021-03-26

Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies

National Cancer Institute (NCI)

Phase 1/2 Completed
40 enrolled 32 charts
CNS

Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡